行情

HTBX

HTBX

Heat Biologics
NASDAQ

实时行情|Nasdaq Last Sale

0.5421
+0.0115
+2.17%
盘后: 0.5399 -0.0022 -0.41% 16:13 04/02 EDT
开盘
0.5400
昨收
0.5306
最高
0.5500
最低
0.5100
成交量
354.11万
成交额
--
52周最高
1.270
52周最低
0.1950
市值
4,303.41万
市盈率(TTM)
-0.7932
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测HTBX价格均价为5.00,最高价位8.00,最低价为2.000。

EPS

HTBX 新闻

更多
  • 60%的美国人认为经济"糟糕" 而1月份时67%认为经济"良好"
  • 新浪美股 · 39分钟前
  • 瑞幸爆出财务造假丑闻 股价一度狂跌八成
  • 新浪美股 · 1小时前
  • 特朗普称沙特和俄罗斯同意减产约1000万桶 但消息未获沙特证实
  • 新浪美股 · 1小时前
  • 特朗普宣称石油减产遭“打脸” 油价经历过山车行情
  • 新浪财经-自媒体综合 · 1小时前

所属板块

生物技术和医学研究
+2.93%
制药与医学研究
+2.57%

热门股票

代码
价格
涨跌幅

HTBX 简况

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
展开

微牛提供Heat Biologics Inc(NASDAQ-HTBX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的HTBX股票新闻,以帮助您做出投资决策。